Professor, Pathology, University of Maryland School of Medicine
Internal Medicine
Dr. Archibald J. Mixson III, MD
|
|
Give Review
Archibald J. Mixson III, MD practices Internal Medicine. He graduated from Emory University School of Medicine. Emory University School of Medicine is ranked 23/42 in Research/PrimaryCare. He received awards:"Awarded 7 US and European Patents", "Their lead product utilizes an HK peptide as a carrier of siRNA for improved wound healing", "Selected to Marquis Whos Who in the World", "Selected to Marquis Whos Who in America", "Americas Top Physicians" and "Boots Thyroid Research Clinical Fellowship Award Finalist". Archibald J. Mixson III, MD is a published doctor. He published 43 publications, including: 'Systemic gene therapy with p53 inhibits breast cancer: recent advances and therapeutic implications.'
Publications
- siRNA nanoparticles: the future of RNAi therapeutics for oncology?
- Increased tumor distribution and expression of histidine-rich plasmid polyplexes.
- Direct observation of dynamic mechanical regulation of DNA condensation by environmental stimuli.
- Enhancement of antifungal activity by integrin-targeting of branched histidine rich peptides.
- Enhanced silencing and stabilization of siRNA polyplexes by histidine-mediated hydrogen bonds.
- Surface-Modified HK:siRNA Nanoplexes with Enhanced Pharmacokinetics and Tumor Growth Inhibition.
- Alteration in the IL-2 signal peptide affects secretion of proteins in vitro and in vivo.
- Modified branched peptides with a histidine-rich tail enhance in vitro gene transfection.
- Highly branched HK peptides are effective carriers of siRNA.
- Synthetic histidine-rich peptides inhibit Candida species and other fungi in vitro: role of endocytosis and treatment implications.
- A branched histidine/lysine peptide, H2K4b, in complex with plasmids encoding antitumor proteins inhibits tumor xenografts.
- Histidine-lysine peptides as carriers of nucleic acids.
- Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth.
- Leveraging therapeutic potential of multi-targeted siRNA inhibitors.
- Selective modification of HK peptides enhances siRNA silencing of tumor targets in vivo.
- Systemic delivery of HK Raf-1 siRNA polyplexes inhibits MDA-MB-435 xenografts.
- The proto-oncogenes c-fos and c-jun modulate thyroid hormone inhibition of human thyrotropin beta subunit gene expression in opposite directions.
- Correlations of language abnormalities with localization of mutations in the beta-thyroid hormone receptor in 13 kindreds with generalized resistance to thyroid hormon...
- Characterization of seven novel mutations of the c-erbA beta gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two "hot spot" region...
- Structural analogues of pyrroline 5-carboxylate specifically inhibit its uptake into cells.
- The uptake of pyrroline 5-carboxylate. Group translocation mediating the transfer of reducing-oxidizing potential.
- Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice.
- ADHD and the thyroid controversy.
- Analysis of the binding of 3,3',5-triiodo-L-thyronine and its analogues to mutant human beta 1 thyroid hormone receptors: a model of the hormone binding site.
- Identification of a novel mutation in the gene encoding the beta-triiodothyronine receptor in a patient with apparent selective pituitary resistance to thyroid hormone.
- Thyrotropin-secreting pituitary carcinoma.
- Attention deficit-hyperactivity disorder in people with generalized resistance to thyroid hormone.
- Differential expression of mutant and normal beta T3 receptor alleles in kindreds with generalized resistance to thyroid hormone.
- Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity.
- Gene therapy with p53 and a fragment of thrombospondin I inhibits human breast cancer in vivo.
- In vivo gene therapy with a cationic polymer markedly enhances the antitumor activity of antiangiogenic genes.
- Systemic gene therapy with p53 inhibits breast cancer: recent advances and therapeutic implications.
- Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice.
- Co-polymer of histidine and lysine markedly enhances transfection efficiency of liposomes.
- Branched co-polymers of histidine and lysine are efficient carriers of plasmids.
- Targeting tumor angiogenesis with gene therapy.
- Vaccines targeting the neovasculature of tumors.
- Transporting silence: design of carriers for siRNA to angiogenic endothelium.
- Small interfering RNA targeting Raf-1 inhibits tumor growth in vitro and in vivo.
- Optimal transfection with the HK polymer depends on its degree of branching and the pH of endocytic vesicles.
- Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2.
- DNA delivery to cells in culture using peptides.
Schools
Emory University
Doctors Specialties
- Internal Medicine
Accepted Insurances
Awards
- Awarded 7 US and European Patents
- Their lead product utilizes an HK peptide as a carrier of siRNA for improved wound healing
- Selected to Marquis Who’s Who in the World
- Selected to Marquis Who’s Who in America
- America’s Top Physicians
- Boots Thyroid Research Clinical Fellowship Award Finalist
Education
-
National Institutes of Health Clinical Center -
Emory University -
Emory University School of Medicine -
Vanderbilt University
Hospital
-
University of Maryland Medical Center
Helpful Reviews
Similar Doctors
|
|
Rebecca P. Abrahams |
|
|
Dr. Michael C. Flanagan, MD |
|
|
Dr. Qandeel H. Soomro, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ihuoma G. Emenuga, MD |
|
|
Dr. Silviu Ziscovici, MD |
|
|
Dr. Susan Leibenhaut, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott Koenig, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kelly J. Tanenholz, MD
This Doctor is OpenDoctor Recommended.
|